April 1, 2021
A combination therapy of Eisai’s multikinase inhibitor Lenvima (lenvatinib) and MSD’s PD-1 inhibitor Keytruda (pembrolizumab) was filed in Japan for the first time, initially for the treatment of advanced renal cell carcinoma (RCC), the partners said on March 31. The...read more